Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection. (December 2021)
- Record Type:
- Journal Article
- Title:
- Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection. (December 2021)
- Main Title:
- Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
- Authors:
- Saia, Rafael Simone
Giusti, Humberto
Luis-Silva, Fábio
Pedroso, Karina de Jesus Bonicenha
Auxiliadora-Martins, Maria
Morejón, Karen Mirna Loro
Degiovani, Augusto Marcussi
Cadelca, Márcia Regina
Basile-Filho, Anibal - Abstract:
- ABSTRACT: Objectives: SARS-CoV-2 exhibits tropism for the gastrointestinal tract; however, lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. Methods: SARS-CoV-2 patients were enrolled in 5 medical centres in São Paulo, Brazil and their clinical characteristics and laboratory findings recorded. At admission, day 7 and day 14 of hospitalisation, plasma and urine samples were collected, and cytokine levels and intestinal fatty acid-binding protein (I-FABP) concentrations measured. Results: COVID-19 patients displayed ≈48-, 74- and 125-fold increased urinary I-FABP levels at admission ( n= 283; P <0.001), day 7 ( n =142; P <0.01) and day 14 ( n =75; P <0.01) of hospitalisation. Critically ill patients and nonsurvivors showed higher I-FABP concentrations compared with patients with less severe illness. At admission, infected patients demonstrated enhanced production of plasma interferon (IFN)-γ and interleukin (IL)-6. The receiver operating characteristic curve suggested I-FABP as a biomarker for COVID-19 disease severity at admission ( P <0.0001; Youden index=6.89; area under the curve=0.699). Patients with I-FABP ≥6.89 showed higher IL-6 and C-reactive protein levels ( P <0.001) at admission and had a prolonged length of hospital stay. Conclusions: Our findings revealed damage to enterocytes in SARS-CoV-2 infection, which is associated with illness severity, poor prognosis and exacerbated inflammatory response.
- Is Part Of:
- International journal of infectious diseases. Volume 113(2021)
- Journal:
- International journal of infectious diseases
- Issue:
- Volume 113(2021)
- Issue Display:
- Volume 113, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 113
- Issue:
- 2021
- Issue Sort Value:
- 2021-0113-2021-0000
- Page Start:
- 82
- Page End:
- 86
- Publication Date:
- 2021-12
- Subjects:
- intestinal epithelial cells -- cytokines -- inflammation -- COVID-19 -- interleukin-6
Communicable diseases -- Periodicals
Communicable Diseases -- Periodicals
Communicable diseases
Periodicals
Electronic journals
616.9 - Journal URLs:
- http://bibpurl.oclc.org/web/73769 ↗
http://www.journals.elsevier.com/international-journal-of-infectious-diseases/ ↗
http://www.sciencedirect.com/science/journal/12019712 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/12019712 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/12019712 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijid.2021.09.051 ↗
- Languages:
- English
- ISSNs:
- 1201-9712
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.304750
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20091.xml